Discontinued ProductD-(+)-threo-3-Hydroxyaspartic acid (Cat. No. 0182) has been withdrawn from sale for commercial reasons.
Potent, competitive, transportable inhibitor of L-glutamate and L-aspartate uptake. Less active than (L)-isomer (Cat. No. 0183).
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
References are publications that support the biological activity of the product.
Johnston et al (1980) Potentiation of L-glutamate and L-aspartate excitation of cat spinal neurones by the stereoisomers of threo-3-hydroxyaspartate. J.Neurochem. 34 241 PMID: 7452241
McBean and Roberts (1985) Neurotoxicity of L-glutamate and DL-threo-3-hydroxyaspartate in the rat striatum. J.Neurochem. 44 247 PMID: 2856883
View Related Products by Product Action
Keywords: D-(+)-threo-3-Hydroxyaspartic acid, D-(+)-threo-3-Hydroxyaspartic acid supplier, Glutamate, Transporters, 0182, Tocris Bioscience
Citations for D-(+)-threo-3-Hydroxyaspartic acid
Citations are publications that use Tocris products.
Currently there are no citations for D-(+)-threo-3-Hydroxyaspartic acid.
Reviews for D-(+)-threo-3-Hydroxyaspartic acid
There are currently no reviews for this product. Be the first to review D-(+)-threo-3-Hydroxyaspartic acid and earn rewards!
Have you used D-(+)-threo-3-Hydroxyaspartic acid?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.
Huntington's Disease Poster
Huntington's disease (HD) is a monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the MSN intracellular signaling pathways implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.